The estimated Net Worth of James R Largent is at least 174 千$ dollars as of 2 November 2021. Mr. Largent owns over 10,000 units of Alimera Sciences stock worth over 71,890$ and over the last 13 years he sold ALIM stock worth over 0$. In addition, he makes 101,930$ as Lead Independent Director at Alimera Sciences.
James has made over 2 trades of the Alimera Sciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ALIM stock worth 43,100$ on 2 November 2021.
The largest trade he's ever made was buying 10,000 units of Alimera Sciences stock on 2 November 2021 worth over 43,100$. On average, James trades about 929 units every 51 days since 2011. As of 2 November 2021 he still owns at least 13,000 units of Alimera Sciences stock.
You can see the complete history of Mr. Largent stock trades at the bottom of the page.
James R. Largent serves as Lead Independent Director of the Company. He has been a member of the Board since 2011 and served as chairman from May 2016 to January 2019, when he became Lead Independent Director. Mr. Largent has worked extensively within the medical industry. He most recently served as a medical and pharmaceutical consultant, including work with the U.S. ophthalmic device company, Eyeonics Inc. In his role as a consultant, he has also assisted a multinational pharmaceutical and medical device company in the evaluation of strategic targets. Prior to this, Mr. Largent served in various senior management positions at Allergan, Inc., including as vice president of strategic planning where he fostered licensing deals to build product pipelines. Earlier in his career, he was vice president of strategic marketing at Allergan Medical Optics, Inc. Mr. Largent also held positions of increasing responsibility in the marketing and sales departments at Allergan and Pharmacia Ophthalmics. In addition to serving on the Board, he previously served on the board of directors of each of Tear Science, Inc., a privately held developer of diagnostic and therapeutic devices for the treatment of patients with dry eye disease, and SOLX Inc., a privately held company focused on the surgical treatment of glaucoma. Mr. Largent earned a B.A. in chemistry and an M.B.A., both from the University of California, Irvine. The Board believes that Mr. Largent should continue to serve as a director of the Company, in light of its business and structure, for the following reasons: his valuable contributions to the Company in recent years and his 30+ years of experience in pharmaceutical and medical devices, including in the role of vice president of strategic marketing and as a leading industry consultant.
As the Lead Independent Director of Alimera Sciences, the total compensation of James Largent at Alimera Sciences is 101,930$. There are 8 executives at Alimera Sciences getting paid more, with Richard Eiswirth having the highest compensation of 977,025$.
James Largent is 70, he's been the Lead Independent Director of Alimera Sciences since 2019. There are no older and 15 younger executives at Alimera Sciences.
James's mailing address filed with the SEC is 6310 TOWN SQUARE, SUITE 400, ALPHARETTA, GA, 30005.
Over the last 15 years, insiders at Alimera Sciences have traded over 14,704,529$ worth of Alimera Sciences stock and bought 8,598,915 units worth 59,337,384$ . The most active insiders traders include Capital, Llc Armistice Capi...、Nicole Vitullo、Jesse I Treu. On average, Alimera Sciences executives and independent directors trade stock every 32 days with the average trade being worth of 468,137$. The most recent stock trade was executed by Partners Lpjohnson David Ed... on 14 September 2023, trading 579,000 units of ALIM stock currently worth 1,962,810$.
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Alimera Sciences executives and other stock owners filed with the SEC include: